Executive Director of Discovery Chemistry
Shifeng Pan, Ph.D.,
Dr. Pan currently serves as Executive Director of Medicinal Chemistry at the Genomics Institute of the Novartis Research Foundation (GNF), where he is responsible for medicinal chemistry efforts at the Institute. He leads a team of ~80 chemists who are working to discover small molecule therapeutics and drug conjugates across multiple disease areas. Since joining GNF in 1999 as one of the founding chemists, he has directly contributed to five clinical candidates. LDE225 (sonidegib), a smoothened antagonist, is in registration for advanced basal cell carcinoma. Two projects (BAF312 and LGX818) have achieved positive clinical PoC and entered registration trials. WNT974, a first-in-class Porcupine inhibitor, is currently in Phase I trials. In 2010, he received the prestigious VIVA award as a Novartis Leading Scientist. Dr. Pan received his Ph.D. in organic chemistry from New York University and B.S. in chemistry from Fudan University in Shanghai, China.